The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Daratumumab: First Global Approval
Abstract
Daratumumab (Darzalex™) is a first-in-class, humanized IgG1κ monoclonal antibody that targets the CD38 epitope and was developed by Janssen Biotech and Genmab. Intravenous daratumumab was recently approved via an accelerated approval programme in the USA for patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent. The drug is in preregistration for this indication in the EU and Canada. In a phase II trial in patients with previously treated (as described above) relapsed or refractory multiple myeloma, monotherapy with daratumumab 16 mg/kg achieved an overall response rate of approximately 30 %. This article summarizes the milestones in the development of daratumumab leading to this first approval for multiple myeloma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“On the basis of these findings, daratumumab monotherapy (at a dose of 16 mg per kilogram of body weight) was approved by the Food and Drug Administration and the European Medicines Agency for these patients.11,12”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [11]
Citations
Cites
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117 · cited 4×
“Intravenous daratumumab monotherapy 16 mg/kg was generally well tolerated in clinical trials in patients with relapsed or refractory multiple myeloma [1, 22, 23].”
BackgroundMethodInfluentialde Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Overdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007813 · Cited by 521 · cited 2×
“Phagocytosis was also shown to contribute to daratumumab’s antitumour activity in a leukaemic xenograft mouse model and in multiple myeloma cells with variable levels of CD38 expression isolated from 11 of 12 patients with multiple myeloma [13].”
BackgroundNijhof, I. S., Groen, R. W. J., Lokhorst, H. M., van Kessel, B., Bloem, A. C., van Velzen, J., de Jong-Korlaar, R., Yuan, H., Noort, W. A., Klein, S. K., et al. (2015) · Leukemia · doi:10.1038/leu.2015.123 · Cited by 267
Resolving the daratumumab interference with blood compatibility testing
Chapuy, C. I., Nicholson, R. T., Aguad, M. D., Chapuy, B., Laubach, J. P., Richardson, P. G., Doshi, P., & Kaufman, R. M. (2015) · Transfusion · doi:10.1111/trf.13069 · Cited by 239
van der Veer, M. S., de Weers, M., van Kessel, B., Bakker, J. M., Wittebol, S., Parren, P. W. H. I., Lokhorst, H. M., & Mutis, T. (2011) · Haematologica · doi:10.3324/haematol.2010.030759 · Cited by 218
Nijhof, I. S., Groen, R. W. J., Noort, W. A., van Kessel, B., de Jong-Korlaar, R., Bakker, J., van Bueren, J. J. L., Parren, P. W. H. I., Lokhorst, H. M., van de Donk, N. W. C. J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1813 · Cited by 151
Nijhof, I. S., van Bueren, J. J. L., van Kessel, B., André, P., Morel, Y., Lokhorst, H. M., van de Donk, N. W. C. J., Parren, P. W. H. I., & Mutis, T. (2014) · Haematologica · doi:10.3324/haematol.2014.117531 · Cited by 114
Clemens, P. L., Yan, X., Lokhorst, H. M., Lonial, S., Losic, N., Khan, I., Jansson, R., Ahmadi, T., Lantz, K. A., Zhou, H., et al. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0477-1 · Cited by 90
Phipps, C., Chen, Y., Gopalakrishnan, S. K., & Tan, D. C. L. (2015) · Therapeutic Advances in Hematology · doi:10.1177/2040620715572295 · Cited by 62
Research works printed but not linked: 3
- Genmab. US FDA grants priority review for daratumumab for double refractory multiple myeloma [media release]. http://ir.genmab.com/releasedetail.cfm?ReleaseID=930345 . Accessed 17 Dec 2015.
- Janssen. Janssen’s new drug submission for daratumumab for treatment of multiple myeloma accepted for review by Health Canada [media release]. https://www.janssen.com/canada/sites/www_janssen_com_canada/files/daratumumab_filing_news_release.pdf . Accessed 17 Dec 2015.
- Doshi P, Sasser AK, Axel A, et al. Daratumumab treatment in combination with CHOP or R-CHOP results in the inhibition or regression of tumors in preclinical models of non-hodgkins lymphoma [abstract no. P434]. Haematologica. 2014;99(Suppl 1):138–9.
Cited by
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445
Krejcik, J., Casneuf, T., Nijhof, I. S., Verbist, B., Bald, J., Plesner, T., Syed, K., Liu, K., van de Donk, N. W. C. J., Weiss, B. M., et al. (2016) · Blood · doi:10.1182/blood-2015-12-687749 · Cited by 954
Usmani, S. Z., Weiss, B. M., Plesner, T., Bahlis, N. J., Belch, A., Lonial, S., Lokhorst, H. M., Voorhees, P. M., Richardson, P. G., Chari, A., et al. (2016) · Blood · doi:10.1182/blood-2016-03-705210 · Cited by 407
Wu, L., Seung, E., Xu, L., Rao, E., Lord, D. M., Wei, R. R., Cortez-Retamozo, V., Ospina, B., Posternak, V., Ulinski, G., et al. (2019) · Nature Cancer · doi:10.1038/s43018-019-0004-z · Cited by 259
Metadata
- Authors
- McKeage, K.
- Corresponding author
- McKeage, Kate
- Venue
- Drugs
- Published
- 2016-01-04
- Volume
- 76
- Issue
- 2
- Pages
- 275-281
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W2227353206
- Semantic Scholar
- 612ab9f52eac098f9df975ce7b91741fff0821b6
- Cited by
- 120
- References
- 16
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 12 · 2023: 8 · 2022: 14 · 2021: 13 · 2020: 14 · 2019: 12 · 2018: 12 · 2017: 13 · 2016: 10
- FWCI
- 14.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- daratumumab, CD38, multiple myeloma, monoclonal antibodies, accelerated approval, relapsed/refractory multiple myeloma, drug development, regulatory approval
- MeSH terms
- Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Humans, Multiple Myeloma, Clinical Trials, Phase II as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Daratumumab: First Global Approval. https://app.cochat.ai/papers/10.1007/s40265-015-0536-1
- The paper
- McKeage, K. (2016). Daratumumab: First Global Approval. Drugs. https://doi.org/10.1007/s40265-015-0536-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.